Johnson & Johnson reports two-year Icotyde data for plaque psoriasis treatment

Johnson & Johnson has released two-year data from the Phase 3 ICONIC-LEAD study for Icotyde (icotrokinra), an oral peptide targeting the IL-23 receptor, used in the treatment of moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older.

The data, presented at the Fall Clinical Dermatology (FCD) 2026 conference, demonstrated sustained high rates of skin clearance and patient-reported symptom improvement at 112 weeks. The study indicated a continued favorable safety profile with no new safety signals identified.

"With two-year data that show long-term skin clearance and a consistent safety profile, ICOTYDE is transforming how we think about plaque psoriasis treatment," said Mark Lebwohl, M.D., Professor Emeritus at the Icahn School of Medicine at Mount Sinai and an investigator in the ICONIC-LEAD study.

At week 112, over 70% of Icotyde-treated patients achieved a Psoriasis Area and Severity Index (PASI) 90 score or clear/almost clear skin (Investigator's Global Assessment, IGA 0/1). Approximately 46% of patients maintained complete skin clearance (PASI 100 or IGA 0) from week 64 through week 112. Clinically meaningful improvement in itch was also sustained.

Johnson & Johnson highlighted that these long-term results affirm Icotyde's potential to shift plaque psoriasis treatment paradigms, addressing the chronic nature of the disease with durable outcomes.